Introduction: Advanced stage malignant mesothelioma (asMM) patients have poor prognosis. Several trials investigated the role of programmed cell death protein-1 (PD-1) and its ligand 1 (PD-L1) immune checkpoint inhibitors (ICIs) in pre-treated asMM. Methods: A systematic review of the literature of clinical trials testing single-agent anti PD-1/PD-L1 ICIs in pre-treated asMM was performed. Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS) data were extracted. The predictive role of PD-L1 was assessed. Results: We selected 13 studies including 888 patients. ORR and DCR were 18.1% (95% confidence interval [CI] 13.9–22.8%) and 55.4% (95% CI: 48.1–62.5%), respectively. Median PFS and OS ranged from 2.1 to 5.9 and from 6.7 to 20.9 months, respectively. ORR according to PD-L1 was 27.0% (95% CI: 18.7–36.2%). Conclusions: Anti-PD-(L)1 ICIs might be considered a treatment option for chemotherapy-resistant asMM, even if reliable predictive factors are still lacking.

A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma

Bironzo P.
Co-first
;
De Luca E.;Pignataro D.;Rapetti S. G.;Audisio M.;Bertaglia V.;Paratore C.;Bungaro M.;Reale M. L.;Zichi C.;Capelletto E.;Carnio S.;Passiglia F.;Novello S.;Scagliotti G. V.;Di Maio M.
2022

Abstract

Introduction: Advanced stage malignant mesothelioma (asMM) patients have poor prognosis. Several trials investigated the role of programmed cell death protein-1 (PD-1) and its ligand 1 (PD-L1) immune checkpoint inhibitors (ICIs) in pre-treated asMM. Methods: A systematic review of the literature of clinical trials testing single-agent anti PD-1/PD-L1 ICIs in pre-treated asMM was performed. Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS) data were extracted. The predictive role of PD-L1 was assessed. Results: We selected 13 studies including 888 patients. ORR and DCR were 18.1% (95% confidence interval [CI] 13.9–22.8%) and 55.4% (95% CI: 48.1–62.5%), respectively. Median PFS and OS ranged from 2.1 to 5.9 and from 6.7 to 20.9 months, respectively. ORR according to PD-L1 was 27.0% (95% CI: 18.7–36.2%). Conclusions: Anti-PD-(L)1 ICIs might be considered a treatment option for chemotherapy-resistant asMM, even if reliable predictive factors are still lacking.
172
103639
103650
Avelumab; Immune checkpoint inhibitors; Mesothelioma; Nivolumab; Pembrolizumab
Tagliamento M.; Bironzo P.; Curcio H.; De Luca E.; Pignataro D.; Rapetti S.G.; Audisio M.; Bertaglia V.; Paratore C.; Bungaro M.; Olmetto E.; Artusio E.; Reale M.L.; Zichi C.; Capelletto E.; Carnio S.; Buffoni L.; Passiglia F.; Novello S.; Scagliotti G.V.; Di Maio M.
File in questo prodotto:
File Dimensione Formato  
Tagliamento Bironzo CROH proof.pdf

Accesso aperto

Tipo di file: PREPRINT (PRIMA BOZZA)
Dimensione 8.05 MB
Formato Adobe PDF
8.05 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1848740
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 2
  • ???jsp.display-item.citation.isi??? ND
social impact